-
Aug 02, 2021
F-star Therapeutics to Announce Second Quarter Results and Host Conference Call on August 12, 2021 -
Jul 26, 2021
F-star Therapeutics Provides Interim Update on SB 11285 First-In-Human Dose-Escalation Study in Patients with Advanced Solid Tumors -
Jul 09, 2021
F-star Therapeutics to Present at Upcoming Investor Conferences -
Jul 08, 2021
F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors -
May 17, 2021
F-star Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update -
May 10, 2021
F-star Therapeutics to Announce First Quarter Results and Corporate Update Call on May 17, 2021 -
May 07, 2021
F-star Therapeutics, Inc. Announces Pricing of $65 Million Public Offering of Common Stock -
May 06, 2021
F-star Therapeutics, Inc. Announces Proposed Public Offering of Common Stock -
Apr 29, 2021
Cancer Trial Highlights Potential for Checkpoint Inhibitors -
Apr 19, 2021
Study Published in Nature Shows F-Star’s STING Agonist SB 11285 Enhances Preclinical Efficacy of Radiation Therapy
Pagination
